Radioligand

A radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound - the ligand. The ligand is the target binding site, it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. The different types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, I-125, etc. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable.[1] Radioligands can be used to analyze/characterize receptors, to perform binding assays, to help in diagnostic imaging, and to provide targeted cancer therapy. Radiation is a novel method of treating cancer and is effective in short distances along with being unique/personalizable and causing minimal harm to normal surrounding cells. Furthermore, radioligand binding can provide information about receptor-ligand interactions in vitro and in vivo. Choosing the right radioligand for the desired application is important. The radioligand must be radiochemically pure, stable, and demonstrate a high degree of selectivity, and high affinity for their target.[2]

  1. ^ "Radioligand Therapy". Novartis. Retrieved 2024-03-23.
  2. ^ Radioligand binding assays: From opiate receptors to drug discovery mainstay. (2023, June 30). PerkinElmer Blog. https://blog.perkinelmer.com/posts/radioligand-binding-assays-from-opiate-receptors-to-drug-discovery-mainstay/

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search